Edward Rosfjord
Overview
Explore the profile of Edward Rosfjord including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bennett T, Rizzo J, Yang S, Rosfjord E
J Am Assoc Lab Anim Sci
. 2023 Mar;
62(3):205-211.
PMID: 36990673
Hypodermic needles are sometimes reused in animal research settings to preserve the viability of and to conserve limited quantities of injected material. However, the reuse of needles is strongly discouraged...
2.
Tiberghien A, Vijayakrishnan B, Esfandiari A, Ahmed M, Pardo R, Bingham J, et al.
Mol Cancer Ther
. 2023 Feb;
22(2):254-263.
PMID: 36722141
Antibody-drug conjugates (ADC) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers are currently being evaluated in clinical trials, with encouraging results in Hodgkin and non-Hodgkin lymphomas. The first example of an ADC delivering...
3.
Hooper A, Marquette K, Chang C, Golas J, Jain S, Lam M, et al.
Mol Cancer Ther
. 2022 Jul;
21(9):1462-1472.
PMID: 35793468
Extra domain B splice variant of fibronectin (EDB+FN) is an extracellular matrix protein (ECM) deposited by tumor-associated fibroblasts, and is associated with tumor growth, angiogenesis, and invasion. We hypothesized that...
4.
Gupta P, Jiang Z, Yang B, Manzuk L, Rosfjord E, Yao J, et al.
MAbs
. 2021 Aug;
13(1):1958662.
PMID: 34347577
IL13Rα2 is a cell surface tumor antigen that is overexpressed in multiple tumor types. Here, we studied biodistribution and targeting potential of an anti-IL13Rα2 antibody (Ab) and anti-tumor activity of...
5.
Maresca K, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, et al.
Mol Imaging Biol
. 2021 Jun;
23(6):941-951.
PMID: 34143379
Purpose: A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging...
6.
Root A, Guntas G, Katragadda M, Apgar J, Narula J, Chang C, et al.
MAbs
. 2021 Jan;
13(1):1850395.
PMID: 33459147
We report here the discovery and optimization of a novel T cell retargeting anti-GUCY2C x anti-CD3ε bispecific antibody for the treatment of solid tumors. Using a combination of hybridoma, phage...
7.
Han Y, Kahler J, Piche-Nicholas N, Hu W, Thibault S, Jiang F, et al.
Clin Cancer Res
. 2020 Nov;
27(2):622-631.
PMID: 33148666
Purpose: Mortality due to acute myeloid leukemia (AML) remains high, and the management of relapsed or refractory AML continues to be therapeutically challenging. The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug...
8.
Graziani E, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2068-2078.
PMID: 32747418
The approval of ado-trastuzumab emtansine (T-DM1) in HER2 metastatic breast cancer validated HER2 as a target for HER2-specific antibody-drug conjugates (ADC). Despite its demonstrated clinical efficacy, certain inherent properties within...
9.
Betts A, Clark T, Jasper P, Tolsma J, van der Graaf P, Graziani E, et al.
J Pharmacokinet Pharmacodyn
. 2020 Jul;
47(5):513-526.
PMID: 32710210
A modeling and simulation approach was used for quantitative comparison of a new generation HER2 antibody drug conjugate (ADC, PF-06804103) with trastuzumab-DM1 (T-DM1). To compare preclinical efficacy, the pharmacokinetic (PK)/pharmacodynamic...
10.
Mathur D, Root A, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, et al.
Clin Cancer Res
. 2020 Jan;
26(9):2188-2202.
PMID: 31996389
Purpose: Gastrointestinal cancers remain areas of high unmet need despite advances in targeted and immunotherapies. Here, we demonstrate potent, tumor-selective efficacy with PF-07062119, a T-cell engaging CD3 bispecific targeting tumors...